Posted on 03/02/2009 in Pharmacy Supplier News Actavis has been sued by Warner Chilcott and Mayne Pharma, it has emerged.
The lawsuit alleges it infringed the 161 patent, which covers tetracycline-class oral antibiotic Doryx.
It follows an Abbreviated New Drug Application filed by Actavis, which sought approval to manufacture and sell generic versions of the drug, prior to expiration of the copyright in 2022.
Marketed and sold by Warner Chilcott, the product is available in 75, 100 and 150 mg doses, as part of a licence agreement with Mayne.
Warner Chilcott said in a statement the company and Mayne "intend to vigorously defend the 161 patent and pursue their legal rights".
The legal action follows other cases launched by the companies, which have seen Impax, Sandoz, Mylan and Mutual Pharmaceuticals sued for patent infringement.
In November, Actavis said its third-party division Medis had launched Fosinopril in France.
The release follows the product's patent expiry on November 26th.Other news stories from 03/02/2009
Read more in the Zenopa News Archive
How this news is generated
|
